Eli Lilly and (LLY) Revenue — Quarter Ended Mar 31, 2024
Revenue increased compared with the same quarter last year, but declined from the immediately preceding quarter. This quarterly performance reflects mixed trends against different comparison periods.
Key takeaway
Quarter ended Mar 31, 2024 · FY2024 Q1
Revenue increased compared with the same quarter last year, but declined from the immediately preceding quarter. This quarterly performance reflects mixed trends against different comparison periods.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$8.8B
Revenue reported for this quarter.
Quarter-over-quarter
-6.3%
Change from the immediately preceding quarter.
Year-over-year
+26.0%
Change from the comparable year-ago quarter.
Trailing four quarters
$35.9B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Jun 30, 2023 | $8.3B | +28.1% |
| Sep 30, 2023 | $9.5B | +36.8% |
| Dec 31, 2023 | $9.4B | +28.1% |
| Mar 31, 2024 | $8.8B | +26.0% |
Revenue performance
The reported revenue showed a year-over-year improvement, extending the growth trajectory. However, on a sequential basis, revenue contracted relative to the prior quarter.
Quarterly comparison
When compared with the immediately preceding quarter, revenue was lower. In contrast, revenue was higher than the same quarter one year earlier.
What to watch
Investors may monitor whether the company can sustain its year-over-year revenue growth momentum in future quarters.